SPDL1 and melanoma: Our findings are consistent with sPD-L1 being a marker of aggressive disease in both RCC and melanoma,14 since high sPD-L1 is associated with having progressed from prior VEGFi therapy in patients with RCC and with high LDH (a marker of poor prognosis) in patients with melanoma.